Clinical Features Predict Responsiveness to Imatinib in Platelet-derived Growth Factor Receptor-alpha-negative Hypereosinophilic Syndrome

Overview

Journal Allergy

Specialty Allergy & Immunology

Date 2016 Jan 23

PMID 26797802

Citations 32

Authors

P Khoury

R Desmond

A Pabon

N Holland-Thomas

J M Ware

D C Arthur

R Kurlander

M P Fay

I Maric

A D Klion

Affiliations

Soon will be listed here.

Abstract

Background: With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES).

Methods: Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT00044304: registered at clinicaltrials.gov). The primary outcome was an eosinophil count <1.5 × 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. A retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily ≥ 1 month) were classified according to the criteria used in the prospective study.

Results: Overall, imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of ≥ 4 myeloid features was the sole predictor of response. After ≥ 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remain in remission off therapy for a median of 29 months (range 14-36).

Conclusions: Clinical features of MHES predict imatinib response in PDGFRA-negative HES.

Citing Articles

Imatinib is effective in some PDGFRA/B-negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms.

Loscocco G, Helbig G Br J Haematol. 2024; 205(6):2136-2138.

PMID: 39468717 PMC: 11637715. DOI: 10.1111/bjh.19853.

Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.

Kim D, Kim S, Park S, Byun J, Hong J, Shin D Br J Haematol. 2024; 205(6):2305-2314.

PMID: 39389908 PMC: 11637721. DOI: 10.1111/bjh.19828.

Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis.

Nguyen L, Saha A, Kuykendall A, Zhang L Cancers (Basel). 2024; 16(7).

PMID: 38611061 PMC: 11011008. DOI: 10.3390/cancers16071383.

Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.

Kuang F, Khoury P, Weller P, Wechsler M, Klion A J Allergy Clin Immunol Pract. 2023; 11(9):2666-2671.

PMID: 37507068 PMC: 10527987. DOI: 10.1016/j.jaip.2023.07.026.

HES and EGPA: Two Sides of the Same Coin.

Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F Mayo Clin Proc. 2023; 98(7):1054-1070.

PMID: 37419574 PMC: 10348452. DOI: 10.1016/j.mayocp.2023.02.013.

References

Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C . Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008; 143(5):707-15. DOI: 10.1111/j.1365-2141.2008.07294.x. View

Apperley J, Gardembas M, Melo J, Russell-Jones R, Bain B, Baxter E . Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347(7):481-7. DOI: 10.1056/NEJMoa020150. View

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S . The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007; 92(9):1173-9. DOI: 10.3324/haematol.11420. View

Klion A, Noel P, Akin C, Law M, Gilliland D, Cools J . Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003; 101(12):4660-6. DOI: 10.1182/blood-2003-01-0006. View

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

Ross D, Branford S, Seymour J, Schwarer A, Arthur C, Bartley P . Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010; 24(10):1719-24. DOI: 10.1038/leu.2010.185. View

Pardanani A, Brockman S, Paternoster S, Flynn H, Ketterling R, Lasho T . FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104(10):3038-45. DOI: 10.1182/blood-2004-03-0787. View

Legrand F, Renneville A, Macintyre E, Mastrilli S, Ackermann F, Cayuela J . The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore). 2013; 92(5):e1-e9. PMC: 4553979. DOI: 10.1097/MD.0b013e3182a71eba. View

Jain N, Cortes J, Quintas-Cardama A, Manshouri T, Luthra R, Garcia-Manero G . Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2008; 33(6):837-9. PMC: 4422052. DOI: 10.1016/j.leukres.2008.10.004. View

10.

Valent P, Klion A, Horny H, Roufosse F, Gotlib J, Weller P . Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3):607-612.e9. PMC: 4091810. DOI: 10.1016/j.jaci.2012.02.019. View

11.

Gotlib J, Cools J . Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; 22(11):1999-2010. DOI: 10.1038/leu.2008.287. View

12.

Golub T, Barker G, Lovett M, Gilliland D . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77(2):307-16. DOI: 10.1016/0092-8674(94)90322-0. View

13.

Weller P, Bubley G . The idiopathic hypereosinophilic syndrome. Blood. 1994; 83(10):2759-79. View

14.

Klion A, Robyn J, Akin C, Noel P, Brown M, Law M . Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2003; 103(2):473-8. DOI: 10.1182/blood-2003-08-2798. View

15.

Ogbogu P, Bochner B, Butterfield J, Gleich G, Huss-Marp J, Kahn J . Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009; 124(6):1319-25.e3. PMC: 2829669. DOI: 10.1016/j.jaci.2009.09.022. View

16.

Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A . Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer Chemother Pharmacol. 2011; 67(4):967-9. PMC: 3064899. DOI: 10.1007/s00280-011-1582-3. View

17.

Ross D, Branford S, Seymour J, Schwarer A, Arthur C, Yeung D . Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013; 122(4):515-22. DOI: 10.1182/blood-2013-02-483750. View

18.

Erben P, Gosenca D, Muller M, Reinhard J, Score J, Del Valle F . Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica. 2010; 95(5):738-44. PMC: 2864379. DOI: 10.3324/haematol.2009.016345. View

19.

Helbig G, Hus M, Halasz M, Dudzinski M, Wieclawek A, Stachowicz M . Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Med Oncol. 2011; 29(2):1073-6. DOI: 10.1007/s12032-011-9831-1. View

20.

Klion A, Robyn J, Maric I, Fu W, Schmid L, Lemery S . Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007; 110(10):3552-6. PMC: 2077306. DOI: 10.1182/blood-2007-07-100164. View